PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with ...

Earlier this month, NICE reiterated its position that Spravato should not be used for TRD, after an appeal of earlier rejections by J&J, with a final decision due in mid-December. In the ESCAPE ...

Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Johnson & ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...